Skip to main content
. 2020 May 21;4(3):e363. doi: 10.1097/HS9.0000000000000363

Figure 3.

Figure 3

Kaplan–Meier curves for progression-free survival (A) and overall survival (B) on ibrutinib monotherapy in Waldenström macroglobulinemia patients stratified by treatment status on and off a clinical trial.